ARWR Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.30%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $7,229,502.79

Arrowhead Pharmaceuticals Insider Trading History Chart

Arrowhead Pharmaceuticals Share Price & Price History

^$16.90

▲ +0.81 (5.03%)

As of 07/2/2025 05:00 PM ET

Days: 30 | 90 | 365

Arrowhead Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/11/2025	Christopher Richard Anzalone	CEO	Sell	50,800	$11.49	$583,692.00	3,921,255
4/9/2025	Christopher Richard Anzalone	CEO	Sell	40,322	$10.07	$406,042.54	4,022,055
3/13/2025	Christopher Richard Anzalone	CEO	Sell	51,425	$15.07	$774,974.75	4,062,377
3/4/2025	Christopher Richard Anzalone	CEO	Sell	133,333	$17.02	$2,269,327.66	3,773,802
1/23/2025	Adeoye Y. Olukotun	Director	Sell	959	$21.00	$20,139.00	35,781
1/6/2025	James C. Hamilton	Insider	Sell	32,729	$19.82	$648,688.78	272,122
1/6/2025	Kenneth Allen Myszkowski	CFO	Sell	27,167	$19.83	$538,721.61	473,433
1/6/2025	Patrick C. O'Brien	COO	Sell	29,184	$19.82	$578,426.88	535,201
1/2/2025	Christopher Richard Anzalone	CEO	Sell	11,520	$19.05	$219,456.00	3,764,252
12/27/2024	Adeoye Y. Olukotun	Director	Sell	2,850	$20.00	$57,000.00	36,740
12/23/2024	Christopher Richard Anzalone	CEO	Sell	12,563	$19.59	$246,109.17	3,775,772
12/18/2024	Christopher Richard Anzalone	CEO	Sell	26,712	$21.24	$567,362.88	3,688,335
12/16/2024	William D. Waddill	Director	Sell	3,748	$21.90	$82,081.20	44,125
7/2/2024	Tracie Oliver	Insider	Sell	9,394	$25.28	$237,480.32	127,107
5/2/2024	Victoria Vakiener	Director	Sell	1,799	$23.31	$41,934.69	30,205
3/20/2024	Hongbo Lu	Director	Buy	1,000	$27.50	$27,500.00	33,680
3/18/2024	Hongbo Lu	Director	Buy	1,000	$27.49	$27,490.00	31,680
3/6/2024	Kenneth Allen Myszkowski	CFO	Sell	40,000	$35.19	$1,407,600.00	400,600
1/31/2024	Christopher Richard Anzalone	CEO	Sell	57,499	$32.35	$1,860,092.65	3,715,048
1/12/2024	James C. Hamilton	Insider	Sell	7,940	$36.89	$292,906.60	210,851
1/11/2024	Douglas B Given	Director	Sell	2,911	$38.06	$110,792.66	129,711
1/5/2024	James C. Hamilton	Insider	Sell	32,143	$35.18	$1,130,790.74	218,791
1/5/2024	Kenneth Allen Myszkowski	CFO	Sell	16,104	$35.27	$567,988.08	440,600
1/5/2024	Patrick C. O'Brien	COO	Sell	22,841	$35.27	$805,602.07	464,385
1/3/2024	James C. Hamilton	Insider	Sell	6,300	$32.19	$202,797.00	175,934
1/3/2024	Patrick C. O'Brien	COO	Sell	8,749	$32.28	$282,417.72	403,826
1/2/2024	Christopher Richard Anzalone	CEO	Sell	9,952	$31.01	$308,611.52	3,715,048
12/20/2023	Christopher Richard Anzalone	CEO	Sell	12,000	$28.54	$342,480.00	3,725,000
11/20/2023	Javier San Martin	Insider	Sell	19,700	$28.80	$567,360.00	131,800
10/25/2023	Christopher Richard Anzalone	CEO	Sell	24,338	$24.21	$589,222.98	3,737,000
9/28/2023	Victoria Vakiener	Director	Sell	1,550	$26.33	$40,811.50	21,734
9/18/2023	Christopher Richard Anzalone	CEO	Sell	57,755	$28.12	$1,624,070.60	3,761,338
7/3/2023	Tracie Oliver	Insider	Sell	8,925	$35.31	$315,141.75	61,575
6/30/2023	James C. Hamilton	Insider	Sell	3,000	$35.53	$106,590.00	188,484
6/27/2023	Kenneth Allen Myszkowski	CFO	Sell	15,000	$36.20	$543,000.00	381,704
5/5/2023	Douglas B Given	Director	Sell	6,500	$40.90	$265,850.00	117,635
5/3/2023	Christopher Richard Anzalone	CEO	Sell	54,928	$39.14	$2,149,881.92	3,761,338
3/3/2023	Adeoye Y. Olukotun	Director	Sell	11,350	$32.65	$370,577.50	7,867
2/27/2023	Douglas B Given	Director	Sell	875	$32.62	$28,542.50	13,000
1/9/2023	William D. Waddill	Director	Sell	3,200	$30.00	$96,000.00	28,950
1/5/2023	James C. Hamilton	Insider	Sell	13,803	$37.40	$516,232.20	191,484
1/5/2023	Patrick C. O'Brien	COO	Sell	15,000	$37.39	$560,850.00	413,375
1/3/2023	James C. Hamilton	Insider	Sell	10,338	$38.38	$396,772.44	145,287
1/3/2023	Patrick C. O'Brien	COO	Sell	17,500	$38.33	$670,775.00	363,375
12/29/2022	Kenneth Allen Myszkowski	CFO	Sell	30,625	$40.00	$1,225,000.00	336,704
11/21/2022	Javier San Martin	Insider	Sell	19,500	$29.99	$584,805.00	91,500

SEC Filings (Institutional Ownership Changes) for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

62.61% of Arrowhead Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Arrowhead Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
6/18/2025	Voya Investment Management LLC	32,184	$0.41M	0.0%	-40.2%	0.023%
5/29/2025	Rhumbline Advisers	345,979	$4.41M	0.0%	-9.0%	0.251%
5/20/2025	Focus Partners Wealth	16,252	$0.21M	0.0%	+1,339.5%	0.012%
5/19/2025	UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC	4,785,062	$60.96M	0.0%	+138.0%	3.465%
5/16/2025	Woodline Partners LP	562,175	$7.16M	0.0%	-33.1%	0.407%
5/16/2025	Empowered Funds LLC	15,252	$0.19M	0.0%	+6.9%	0.011%
5/16/2025	Goldman Sachs Group Inc.	1,741,666	$22.19M	0.0%	+34.6%	1.261%
5/16/2025	Dynamic Technology Lab Private Ltd	26,969	$0.34M	0.0%	+40.9%	0.020%
5/16/2025	Millennium Management LLC	690,796	$8.80M	0.0%	-24.5%	0.500%
5/16/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	238,328	$3.05M	0.0%	-1.8%	0.173%
5/16/2025	AQR Capital Management LLC	40,506	$0.51M	0.0%	N/A	0.029%
5/16/2025	ADAR1 Capital Management LLC	56,300	$0.72M	0.1%	+336.4%	0.041%
5/15/2025	Royal Bank of Canada	45,239	$0.58M	0.0%	+30.2%	0.033%
5/15/2025	Magnetar Financial LLC	70,375	$0.90M	0.0%	+389.8%	0.051%
5/15/2025	Siren L.L.C.	2,669,880	$34.01M	2.0%	-8.0%	1.933%
5/15/2025	Tema Etfs LLC	29,893	$0.38M	0.1%	-51.4%	0.022%
5/14/2025	Rafferty Asset Management LLC	192,791	$2.46M	0.0%	+39.3%	0.140%
5/14/2025	Corebridge Financial Inc.	62,556	$0.80M	0.0%	-68.6%	0.046%
5/14/2025	Comerica Bank	42,343	$0.54M	0.0%	+17.9%	0.031%
5/14/2025	MetLife Investment Management LLC	71,963	$0.92M	0.0%	-49.0%	0.052%
5/14/2025	Pale Fire Capital SE	12,221	$0.16M	0.0%	N/A	0.009%
5/14/2025	Jump Financial LLC	88,204	$1.12M	0.0%	-37.4%	0.064%
5/14/2025	T. Rowe Price Investment Management Inc.	2,528,982	$32.22M	0.0%	+0.9%	1.842%
5/14/2025	Capital Fund Management S.A.	163,146	$2.08M	0.0%	N/A	0.119%
5/14/2025	Hsbc Holdings PLC	13,850	$0.17M	0.0%	N/A	0.010%
5/14/2025	Wellington Management Group LLP	52,614	$0.67M	0.0%	-5.0%	0.038%
5/13/2025	Northern Trust Corp	1,210,813	$15.43M	0.0%	-18.4%	0.882%
5/13/2025	Aberdeen Group plc	1,072,827	$13.67M	0.0%	+138.4%	0.781%
5/13/2025	Fox Run Management L.L.C.	55,404	$0.71M	0.1%	+5.8%	0.040%
5/13/2025	Oak Ridge Investments LLC	33,734	$0.43M	0.0%	+2.5%	0.025%
5/13/2025	E Fund Management Co. Ltd.	18,017	$0.23M	0.0%	N/A	0.013%
5/13/2025	Russell Investments Group Ltd.	5,629	$72K	0.0%	-96.9%	0.004%
5/13/2025	Resona Asset Management Co. Ltd.	10,318	$0.14M	0.0%	-53.7%	0.008%
5/13/2025	HighTower Advisors LLC	112,417	$1.43M	0.0%	+49.8%	0.082%
5/12/2025	Public Sector Pension Investment Board	399,870	$5.09M	0.0%	N/A	0.291%
5/12/2025	Nuveen LLC	337,878	$4.31M	0.0%	N/A	0.246%
5/12/2025	King Luther Capital Management Corp	83,590	$1.07M	0.0%	+8.6%	0.061%
5/12/2025	Invesco Ltd.	314,080	$4M	0.0%	+78.2%	0.229%
5/12/2025	Swiss National Bank	216,900	$2.76M	0.0%	-1.4%	0.158%
5/12/2025	Mitsubishi UFJ Asset Management Co. Ltd.	14,476	$0.18M	0.0%	+9.0%	0.011%
5/12/2025	Maryland State Retirement & Pension System	36,992	$0.47M	0.0%	N/A	0.027%
5/9/2025	Mutual of America Capital Management LLC	18,363	$0.23M	0.0%	-72.0%	0.013%
5/9/2025	CenterBook Partners LP	66,913	$0.85M	0.1%	-80.9%	0.049%
5/9/2025	Deutsche Bank AG	249,989	$3.19M	0.0%	-3.5%	0.182%
5/9/2025	Ontario Teachers Pension Plan Board	45,769	$0.58M	0.0%	N/A	0.033%
5/9/2025	Charles Schwab Investment Management Inc.	1,035,290	$13.19M	0.0%	+1.7%	0.754%
5/9/2025	Vanguard Group Inc.	13,202,562	$168.20M	0.0%	+8.4%	9.615%
5/9/2025	Privium Fund Management B.V.	629,214	$8.02M	2.1%	+65.3%	0.458%
5/9/2025	PNC Financial Services Group Inc.	2,666	$34K	0.0%	-23.5%	0.002%
5/8/2025	US Bancorp DE	33,101	$0.42M	0.0%	-4.1%	0.024%
5/8/2025	XTX Topco Ltd	10,421	$0.13M	0.0%	N/A	0.008%
5/8/2025	GSA Capital Partners LLP	71,685	$0.91M	0.1%	+514.4%	0.052%
5/7/2025	TD Asset Management Inc	56,606	$0.72M	0.0%	-11.3%	0.041%
5/6/2025	Pinnacle Associates Ltd.	141,162	$1.80M	0.0%	N/A	0.103%
5/6/2025	Universal Beteiligungs und Servicegesellschaft mbH	13,622	$0.17M	0.0%	N/A	0.010%
5/5/2025	IFP Advisors Inc	15,813	$0.20M	0.0%	-23.9%	0.012%
5/2/2025	Victory Capital Management Inc.	45,283	$0.58M	0.0%	+99.2%	0.033%
5/2/2025	Edgestream Partners L.P.	305,507	$3.89M	0.1%	+153.7%	0.222%
5/1/2025	CWM LLC	4,401	$56K	0.0%	+134.3%	0.003%
5/1/2025	Louisiana State Employees Retirement System	59,400	$0.76M	0.0%	+72.2%	0.043%
5/1/2025	Mutual of America Capital Management LLC	18,363	$0.23M	0.0%	-72.0%	0.013%
4/30/2025	Cerity Partners LLC	11,078	$0.14M	0.0%	N/A	0.008%
4/30/2025	China Universal Asset Management Co. Ltd.	25,293	$0.32M	0.0%	-4.1%	0.018%
4/29/2025	Bank of New York Mellon Corp	776,039	$9.89M	0.0%	-6.5%	0.565%
4/28/2025	Principal Financial Group Inc.	629,075	$8.01M	0.0%	+117.8%	0.458%
4/28/2025	Oregon Public Employees Retirement Fund	28,884	$0.37M	0.0%	+14.0%	0.021%
4/28/2025	Teacher Retirement System of Texas	30,143	$0.38M	0.0%	-9.1%	0.022%
4/25/2025	New York State Teachers Retirement System	148,376	$1.89M	0.0%	+6.9%	0.108%
4/25/2025	Amalgamated Bank	35,744	$0.46M	0.0%	-37.0%	0.026%
4/25/2025	KBC Group NV	7,356	$94K	0.0%	+40.8%	0.005%
4/23/2025	Wealth Effects LLC	170,550	$2.17M	0.9%	+9.4%	0.124%
4/21/2025	State of Alaska Department of Revenue	69,870	$0.89M	0.0%	+393.4%	0.051%
4/17/2025	Exchange Traded Concepts LLC	49,247	$0.63M	0.0%	+31.8%	0.036%
4/17/2025	Pinion Investment Advisors LLC	150,000	$1.91M	0.4%	+100.0%	0.109%
4/15/2025	Assenagon Asset Management S.A.	22,701	$0.29M	0.0%	-57.2%	0.017%
4/15/2025	SG Americas Securities LLC	68,346	$0.87M	0.0%	N/A	0.050%
4/15/2025	GAMMA Investing LLC	2,175	$28K	0.0%	+297.6%	0.002%
4/14/2025	Yousif Capital Management LLC	47,347	$0.60M	0.0%	+5.2%	0.034%
4/8/2025	Rhumbline Advisers	345,979	$4.41M	0.0%	-9.0%	0.252%
4/7/2025	GAMMA Investing LLC	27,710	$3.53M	0.0%	+4,965.8%	0.020%
3/24/2025	Wellington Management Group LLP	55,396	$1.04M	0.0%	-10.5%	0.040%
3/18/2025	California State Teachers Retirement System	105,154	$1.98M	0.0%	-1.1%	0.077%
2/20/2025	Mackenzie Financial Corp	7,299	$0.14M	0.0%	N/A	0.006%
2/19/2025	GF Fund Management CO. LTD.	2,613	$49K	0.0%	N/A	0.002%
2/18/2025	Neo Ivy Capital Management	16,920	$0.32M	0.1%	N/A	0.013%
2/17/2025	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	2,010,129	$37.79M	0.0%	-6.7%	1.607%
2/17/2025	Woodline Partners LP	840,174	$15.80M	0.1%	-3.0%	0.672%
2/17/2025	Squarepoint Ops LLC	86,044	$1.62M	0.0%	-55.6%	0.069%
2/17/2025	Two Sigma Advisers LP	430,700	$8.10M	0.0%	+330.7%	0.344%
2/17/2025	Two Sigma Investments LP	794,373	$14.93M	0.0%	+281.3%	0.635%
2/17/2025	Tidal Investments LLC	21,249	$0.40M	0.0%	-4.8%	0.017%
2/17/2025	Tema Etfs LLC	61,503	$1.16M	0.5%	N/A	0.049%
2/17/2025	Silvercrest Asset Management Group LLC	280,511	$5.27M	0.0%	+24.7%	0.224%
2/17/2025	Sphera Funds Management LTD.	197,550	$3.71M	0.7%	N/A	0.158%
2/17/2025	Rafferty Asset Management LLC	138,377	$2.60M	0.0%	-23.5%	0.111%
2/17/2025	ProShare Advisors LLC	45,330	$0.85M	0.0%	+28.3%	0.036%
2/17/2025	Nomura Holdings Inc.	16,466	$0.31M	0.0%	+54.1%	0.013%
2/17/2025	Nuveen Asset Management LLC	332,749	$6.26M	0.0%	-0.8%	0.266%
2/17/2025	Millennium Management LLC	914,550	$17.19M	0.0%	+41.7%	0.731%
2/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	242,702	$4.56M	0.0%	+15.9%	0.194%

Data available starting January 2016

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Today's Range

Now: $16.90

$15.99

$16.98

50 Day Range

MA: $15.23

$13.01

$16.97

52 Week Range

Now: $16.90

$9.57

$30.41

Volume

1,741,253 shs

Average Volume

1,869,908 shs

Market Capitalization

$2.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93

Who are the company insiders with the largest holdings of Arrowhead Pharmaceuticals?: Arrowhead Pharmaceuticals' top insider shareholders include:
Christopher Richard Anzalone (CEO)
Patrick O'brien (COO)
Kenneth Allen Myszkowski (CFO)
James C Hamilton (Insider)
Martin Javier San (Insider)
Douglas B Given (Director)
Tracie Oliver (Insider)
William D Waddill (Director)
Adeoye Y Olukotun (Director)
Hongbo Lu (Director)
Victoria Vakiener (Director)
Learn More about top insider investors at Arrowhead Pharmaceuticals.